SGRY Price Prediction Next Week
Analysis and Insights
News Sentiment and Analyst Ratings:
Surgery Partners (SGRY) has received mixed analyst ratings recently. RBC Capital and TD Cowen have maintained a Buy rating with price targets of $35.00 and $32.00 respectively, while KeyBanc has a Hold rating. The company reported a Q4 adjusted EPS of 44 cents, beating consensus estimates of 38 cents, but also announced a GAAP net loss of $108.5 million. Additionally, Surgery Partners received a buyout proposal from Bain Capital at $25.75 per share, which may influence short-term price movements.
Technical Analysis:
The stock is currently trading at $24.43, with key Fibonacci levels indicating support at $23.42 and resistance at $24.45 and $24.76. The RSI is at 50.12, indicating a neutral position, while the MACD is slightly bearish at -0.04. The stock is trading near the lower end of its recent Fibonacci range, suggesting potential consolidation or a slight upward move.
Price Prediction and Recommendation:
Based on the current technical indicators and news sentiment, Surgery Partners (SGRY) is expected to trade between $24.20 and $25.00 in the next trading week. The stock may experience a slight upward movement due to the buyout proposal, but the overall technical indicators do not suggest a strong bullish trend.
Exact Price Prediction: $24.50
Recommendation: Sell if the stock approaches the buyout offer price of $25.75, as this may act as a resistance level.
SGRY Similar Chart Price Prediction
The price of SGRY is predicted to go up 0.69%, based on the high correlation periods with TVE. The similarity of these two price pattern on the periods is 97.79%.
SGRY
TVE
Up: 0.69%Similarity: 97.79%
SGRY Revenue Forecast
SGRY EPS Forecast
SGRY FAQs
What is SGRY revenue forecast for next quarter？
What is SGRY eps forecast for next quarter？
SGRY Analyst's Forecast
Tao Qiu
Macquarie
Buy
2024-11-19
Price Target
$34
Upside
+45.36%
Macquarie notes that Surgery Partners has declined 31% in the past five trading sessions, with 14% of free-floating shares changing hands since Q3 earnings were reported. The firm's "theories" to explain the recent underperformance include disappointment at free cash flow and EPS downgrades, doubt over takeout prospects, anxiety over the RFK Jr. appointment, and high-yield related pressure, but it thinks "none of the concerns justifies the significant loss of equity value" when Surgery Partners' growth outlook and pipeline remain strong. Macquarie maintains an Outperform rating and $34 price target on the shares.
A.J. Rice
UBS
Strong Buy
2024-10-14
Price Target
$38
Upside
+19.69%
